Anticoagulation in acute blood purification for acute renal failure in critical care

Contributions to Nephrology

Volumn 166, Issue , 2010, Pages 119-125

  Shinoda, Toshio ^a  

^a Kawakita General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; GUANIDINE DERIVATIVE; NAFAMSTAT;

ACUTE KIDNEY FAILURE; BLEEDING; HUMAN; INTENSIVE CARE; JAPAN; METHODOLOGY; RENAL REPLACEMENT THERAPY; REVIEW;

ANTICOAGULANTS; CRITICAL CARE; GUANIDINES; HEMORRHAGE; HUMANS; JAPAN; KIDNEY FAILURE, ACUTE; RENAL REPLACEMENT THERAPY;

EID: 84925941478     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000314861     Document Type: Article

References (13)

1. Caplan AA: Continuous renal replacement therapy (CRRT) in the intensive care unit. J Intensive Care Med 1998;13:85-105.
2. Ronco C, Bellomo R, Ricci Z: Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 2001;16(suppl): S67-S72.
3. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M: Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 2002;6:193-198.
4. Kramer P, Schrader J, Bohnsack W, Grieben G, Grone HJ, Scheler F: Continuous arteriovenous hemofiltration: a new kidney replacement therapy. Proc Eur Dial Transplant Assoc 1981;18:743-749.
5. Ronco C: Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993;40:187-198.
6. Augustine JJ, Sandy D, Seifert TH, Paganini EP: A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis 2004;44:1000-1007.
7. Kumar VA, Craig M, Depner TA, Yeun JY: Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care init. Am J Kidney Dis 2000;36:294-300.
8. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y: Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993;64:376-381.
9. Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993;23:135-141.
10. Koshikawa S, Akizawa T, Mimura N, Ota K, Hirasawa Y, Maekawa M: Effects of low molecular weight heparin as an anticoagulant for hemodialysis patients with bleeding risk: multi-institutional control study with low dose or regional heparinization. Clin Eval 1991;19:541-571.
11. Schrader J, Stibbe W, Armstrong V W, Kandt M, Muche R, Kostering H, Seidel D, Cheler F: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890-896.
12. Hitomi T, Ikari N, Fujii S: Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985;15:164-168.
13. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, Kitamura N: Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991;93:215-217.